Serum microRNA-486-5p expression in obese Egyptian children and its possible association with fatty liver

Mahmoud A Al Azzouny1, Eman G Behiry1, Ola G Behairy2

  • 1Department of Chemical and Clinical Pathology, Faculty of Medicine, Benha University, Egypt.

Insights

MicroRNA-486-5p (miR-486-5p) is elevated in obese children and correlates with obesity markers and fatty liver. This microRNA may predict obesity and nonalcoholic fatty liver disease (NAFLD) susceptibility.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pediatrics

Background:

  • MicroRNAs (miRNAs) play a role in adipogenesis, with white adipose tissue being a key source.
  • Understanding miRNA expression in pediatric obesity is crucial for identifying disease mechanisms.

Purpose of the Study:

  • To evaluate miR-486-5p expression in obese children.
  • To investigate the association between miR-486-5p and nonalcoholic fatty liver disease (NAFLD) in pediatric obesity.

Main Methods:

  • A case-control study involving 100 obese/overweight children and 100 normal-weight children.
  • miR-486-5p expression levels were measured using real-time RT-PCR.

Main Results:

  • Obese children exhibited significantly higher miR-486-5p expression (p < 0.001).
  • miR-486-5p positively correlated with weight, BMI, waist circumference, fat mass, LDL, TG, TC, and fatty liver presence.
  • A cutoff value of 0.44 for miR-486-5p predicted obesity with 60% sensitivity and 90% specificity (AUC 0.736).

Conclusions:

  • Serum miR-486-5p is upregulated in obese and overweight children.
  • miR-486-5p may serve as an independent predictor for obesity and fatty liver susceptibility in children.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
29
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
724
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
25